LTS-201
Huntington’s Disease
Pre-clinicalActive
Key Facts
About Latus Bio
Latus Bio is a private, pre-clinical stage biotech leveraging high-throughput screening and computational methods to discover novel AAV capsids for targeted gene therapy. The company's platform aims to enable tissue-specific delivery, dramatically lower therapeutic doses, reduce toxicity, and decrease manufacturing costs. Its initial pipeline targets severe monogenic CNS disorders, including Huntington's disease and CLN2 Batten disease, with programs advancing toward clinical development.
View full company profileTherapeutic Areas
Other Huntington’s Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Huntington’s Disease Program | Iris Medicine | Preclinical |